Alain Huriez
Role: Associate
Site: CDL-Berlin
Stream: Health
Alain brings over 30 years of experience in Life Sciences and finance. He started his career as a General Practitioner (GP) and then spent ten years in biotechnology drug development and regulatory strategy as vice president of Quintiles (IQVIA) Europe. From 2002 to 2012 he was a life sciences entrepreneur, associate partner at Truffle Capital, and CEO of Neovacs (vaccines) and TcLand-Effimune (now OSE-immuno) (molecular diagnostics, biologics). Alain has successfully founded five French biotechnology companies, including Theravectys (lentivirus vaccine platform) and Samabriva (enabling technology platform). He has been involved in personalized medicine initiatives at the European level, as founder and chairman of EPEMED, the European PErsonalized MEDicine association.
Alain joined the VC firm Advent Life Sciences in 2012. He founded AdBio Partners (formerly Advent France Biotechnology) in 2016.
Alain was the first investor in Orphalan, a commercial stage EU/US company in rare diseases. He has been chairman of the board between 2015 & 2022.
Alain’s medical and biotechnological background, his experience as a serial entrepreneur and a leading executive, his expertise in clinical development as well as his networks, are critical to identifying early-stage biotechnology projects and to mentoring managers towards building successful businesses.